AG真人官方

STOCK TITAN
  1. Home
  2. Sec-filings
  3. BIIB
  4. [Form 4] Biogen Inc. Insider Trading Activity

[Form 4] Biogen Inc. Insider Trading Activity

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
4
Rhea-AI Filing Summary

Form 4 snapshot: Biogen Inc. (BIIB) director Stephen A. Sherwin reported the acquisition of 2,370 shares of common stock on 06/17/2025. The transaction price is recorded as $0.00, indicating a grant or award rather than an open-market purchase. Following the transaction, Sherwin鈥檚 direct beneficial ownership increased to 13,688 shares.

No derivative securities were reported, and there were no dispositions. The filing was signed on 06/18/2025 by attorney-in-fact Wendell Taylor.

Riepilogo del Modulo 4: Il direttore di Biogen Inc. (BIIB), Stephen A. Sherwin, ha comunicato l'acquisizione di 2.370 azioni ordinarie il 17/06/2025. Il prezzo della transazione 猫 indicato come 0,00 $, suggerendo un conferimento o un premio piuttosto che un acquisto sul mercato aperto. Dopo la transazione, la propriet脿 diretta di Sherwin 猫 aumentata a 13.688 azioni.

Non sono stati segnalati titoli derivati n茅 cessioni. Il documento 猫 stato firmato il 18/06/2025 dall鈥檃vvocato procuratore Wendell Taylor.

Resumen del Formulario 4: El director de Biogen Inc. (BIIB), Stephen A. Sherwin, report贸 la adquisici贸n de 2,370 acciones ordinarias el 17/06/2025. El precio de la transacci贸n se registr贸 como $0.00, indicando una concesi贸n o premio en lugar de una compra en mercado abierto. Tras la transacci贸n, la propiedad directa de Sherwin aument贸 a 13,688 acciones.

No se reportaron valores derivados ni disposiciones. El documento fue firmado el 18/06/2025 por el apoderado Wendell Taylor.

Form 4 鞖旍暯: Biogen Inc.(BIIB)鞚� 鞚挫偓 Stephen A. Sherwin鞚� 2025雲� 6鞗� 17鞚检棎 氤错喌欤� 2,370欤茧ゼ 旆摑頄堧嫟瓿� 氤搓碃頄堨姷雼堧嫟. 瓯半灅 臧�瓴╈潃 $0.00搿� 旮半霅橃柎 瓿店皽 鞁滌灔鞐愳劀鞚� 甑Г臧� 鞎勲媽 攵�鞐� 霕愲姅 靸侁笀鞛勳潉 雮橅儉雰呺媹雼�. 瓯半灅 頉� Sherwin鞚� 歆侅爲 氤挫湢 欤检嫕鞚� 13,688欤�搿� 歃濌皜頄堨姷雼堧嫟.

韺岇儩 歃濌秾 氤搓碃電� 鞐嗢棃鞙茧┌ 觳橂秳霃� 鞐嗢棃鞀惦媹雼�. 鞚� 靹滊電� 2025雲� 6鞗� 18鞚� 雽�毽澑 Wendell Taylor鞐� 鞚橅暣 靹滊獏霅橃棃鞀惦媹雼�.

R茅sum茅 du formulaire 4 : Le directeur de Biogen Inc. (BIIB), Stephen A. Sherwin, a d茅clar茅 l鈥檃cquisition de 2 370 actions ordinaires le 17/06/2025. Le prix de la transaction est indiqu茅 脿 0,00 $, ce qui sugg猫re une attribution ou une r茅compense plut么t qu鈥檜n achat sur le march茅 libre. Apr猫s la transaction, la propri茅t茅 directe de Sherwin a augment茅 脿 13 688 actions.

Aucun titre d茅riv茅 n鈥檃 茅t茅 signal茅 et aucune cession n鈥檃 eu lieu. Le d茅p么t a 茅t茅 sign茅 le 18/06/2025 par le mandataire Wendell Taylor.

Formular 4 Zusammenfassung: Biogen Inc. (BIIB) Direktor Stephen A. Sherwin meldete am 17.06.2025 den Erwerb von 2.370 Stammaktien. Der Transaktionspreis wurde mit 0,00 $ angegeben, was auf eine Zuteilung oder Auszeichnung und nicht auf einen Kauf am offenen Markt hinweist. Nach der Transaktion erh枚hte sich Sherwins unmittelbarer Eigentumsanteil auf 13.688 Aktien.

Es wurden keine derivativen Wertpapiere gemeldet und keine Ver盲u脽erungen get盲tigt. Die Einreichung wurde am 18.06.2025 vom Bevollm盲chtigten Wendell Taylor unterzeichnet.

Positive
  • Director increased direct ownership by 2,370 shares, suggesting continued alignment with shareholder interests.
Negative
  • None.

Insights

TL;DR: Minor insider share increase; unlikely to move BIIB.

The grant of 2,370 shares boosts Director Sherwin鈥檚 direct stake to 13,688 shares. Because the shares were awarded at $0, the transaction does not reflect market sentiment or a cash outlay by the insider. Such routine equity compensation events are common and typically carry limited trading impact. Investors may note that ownership is rising rather than falling, but there is no signal of active buying pressure or valuation view. Overall, the disclosure is neutral for Biogen鈥檚 investment thesis.

Riepilogo del Modulo 4: Il direttore di Biogen Inc. (BIIB), Stephen A. Sherwin, ha comunicato l'acquisizione di 2.370 azioni ordinarie il 17/06/2025. Il prezzo della transazione 猫 indicato come 0,00 $, suggerendo un conferimento o un premio piuttosto che un acquisto sul mercato aperto. Dopo la transazione, la propriet脿 diretta di Sherwin 猫 aumentata a 13.688 azioni.

Non sono stati segnalati titoli derivati n茅 cessioni. Il documento 猫 stato firmato il 18/06/2025 dall鈥檃vvocato procuratore Wendell Taylor.

Resumen del Formulario 4: El director de Biogen Inc. (BIIB), Stephen A. Sherwin, report贸 la adquisici贸n de 2,370 acciones ordinarias el 17/06/2025. El precio de la transacci贸n se registr贸 como $0.00, indicando una concesi贸n o premio en lugar de una compra en mercado abierto. Tras la transacci贸n, la propiedad directa de Sherwin aument贸 a 13,688 acciones.

No se reportaron valores derivados ni disposiciones. El documento fue firmado el 18/06/2025 por el apoderado Wendell Taylor.

Form 4 鞖旍暯: Biogen Inc.(BIIB)鞚� 鞚挫偓 Stephen A. Sherwin鞚� 2025雲� 6鞗� 17鞚检棎 氤错喌欤� 2,370欤茧ゼ 旆摑頄堧嫟瓿� 氤搓碃頄堨姷雼堧嫟. 瓯半灅 臧�瓴╈潃 $0.00搿� 旮半霅橃柎 瓿店皽 鞁滌灔鞐愳劀鞚� 甑Г臧� 鞎勲媽 攵�鞐� 霕愲姅 靸侁笀鞛勳潉 雮橅儉雰呺媹雼�. 瓯半灅 頉� Sherwin鞚� 歆侅爲 氤挫湢 欤检嫕鞚� 13,688欤�搿� 歃濌皜頄堨姷雼堧嫟.

韺岇儩 歃濌秾 氤搓碃電� 鞐嗢棃鞙茧┌ 觳橂秳霃� 鞐嗢棃鞀惦媹雼�. 鞚� 靹滊電� 2025雲� 6鞗� 18鞚� 雽�毽澑 Wendell Taylor鞐� 鞚橅暣 靹滊獏霅橃棃鞀惦媹雼�.

R茅sum茅 du formulaire 4 : Le directeur de Biogen Inc. (BIIB), Stephen A. Sherwin, a d茅clar茅 l鈥檃cquisition de 2 370 actions ordinaires le 17/06/2025. Le prix de la transaction est indiqu茅 脿 0,00 $, ce qui sugg猫re une attribution ou une r茅compense plut么t qu鈥檜n achat sur le march茅 libre. Apr猫s la transaction, la propri茅t茅 directe de Sherwin a augment茅 脿 13 688 actions.

Aucun titre d茅riv茅 n鈥檃 茅t茅 signal茅 et aucune cession n鈥檃 eu lieu. Le d茅p么t a 茅t茅 sign茅 le 18/06/2025 par le mandataire Wendell Taylor.

Formular 4 Zusammenfassung: Biogen Inc. (BIIB) Direktor Stephen A. Sherwin meldete am 17.06.2025 den Erwerb von 2.370 Stammaktien. Der Transaktionspreis wurde mit 0,00 $ angegeben, was auf eine Zuteilung oder Auszeichnung und nicht auf einen Kauf am offenen Markt hinweist. Nach der Transaktion erh枚hte sich Sherwins unmittelbarer Eigentumsanteil auf 13.688 Aktien.

Es wurden keine derivativen Wertpapiere gemeldet und keine Ver盲u脽erungen get盲tigt. Die Einreichung wurde am 18.06.2025 vom Bevollm盲chtigten Wendell Taylor unterzeichnet.

SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
SHERWIN STEPHEN A
(Last) (First) (Middle)
BIOGEN INC.
225 BINNEY STREET
(Street)
CAMBRIDGE MA 02142
(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
BIOGEN INC. [ BIIB ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
X Director 10% Owner
Officer (give title below) Other (specify below)
3. Date of Earliest Transaction (Month/Day/Year)
06/17/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
 6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 06/17/2025 A 2,370 A $0 13,688 D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Explanation of Responses:
/s/ Wendell Taylor, Attorney in Fact for Stephen Sherwin 06/18/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source:

FAQ

How many Biogen (BIIB) shares did Stephen A. Sherwin acquire?

2,370 shares of common stock were acquired on 06/17/2025.

What is Stephen Sherwin鈥檚 total BIIB share count after the transaction?

He now owns 13,688 shares directly.

Was cash paid for the acquired BIIB shares?

No. The Form 4 lists the transaction price as $0.00, indicating a grant or award.

Does the filing include any derivative securities?

No derivative securities were reported in this Form 4.

What is Stephen Sherwin鈥檚 role at Biogen?

He is listed as a Director of Biogen Inc.

When was the Form 4 signed and filed?

The form was signed on 06/18/2025 and filed shortly thereafter.
Stock BIIB logo
Biogen Inc

NASDAQ:BIIB

BIIB Rankings

#768 Ranked by Market Cap
N/A Ranked by Dividends

BIIB Latest News

Jun 30, 2025
Biogen Initiates Phase 3 Study of Felzartamab for the Treatment of Primary Membranous Nephropathy
Jun 27, 2025
New Data for Nusinersen Underscore Biogen鈥檚 Commitment to Advancing Clinical Research to Improve Outcomes in SMA
Jun 25, 2025
Biogen to Advance Investigational Spinal Muscular Atrophy Asset to Registrational Studies Based on Positive Interim Phase 1 Results
Jun 18, 2025
Biogen Initiates Phase 3 Pediatric Study of Omaveloxolone for the Treatment of Friedreich Ataxia
Jun 12, 2025
Dapirolizumab Pegol Phase 3 Data in SLE Presented at the Annual European Congress of Rheumatology (EULAR) Show Improvement in Fatigue and Reduction in Disease Activity

BIIB Latest SEC Filings

Jun 23, 2025
[8-K] Biogen Inc. Reports Material Event
Jun 18, 2025
[Form 4] Biogen Inc. Insider Trading Activity
Jun 18, 2025
[Form 4] Biogen Inc. Insider Trading Activity
Jun 18, 2025
[Form 4] Biogen Inc. Insider Trading Activity
Jun 18, 2025
[Form 4] Biogen Inc. Insider Trading Activity

BIIB Stock Data

18.60B
146.22M
0.21%
94.46%
2.54%
Drug Manufacturers - General
Biological Products, (no Disgnostic Substances)
United States
CAMBRIDGE